Triple Combo Therapy Targets Chemo-Resistant Colorectal Cancer in Phase I Trial
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
Summary
Microsatellite stable metastatic colorectal cancer is one of the most treatment-resistant cancers, historically failing to respond to immunotherapy. This phase I trial from City of Hope Medical Center tested whether combining regorafenib, a multi-kinase inhibitor, with ipilimumab and nivolumab, two immune checkpoint blockers, could overcome that resistance. The rationale is that regorafenib may reshape the tumor's immune environment, making it more vulnerable to attack by the immune system. Thirty-nine patients who had already failed chemotherapy were enrolled. The primary goal was to find the safest effective dose of regorafenib within the combination. The trial has now completed, and results may offer a new strategy for a patient population with very limited options.
Detailed Summary
Metastatic colorectal cancer that is microsatellite stable represents a major unmet need in oncology. Unlike microsatellite instable tumors, which respond well to immune checkpoint inhibitors, the microsatellite stable subtype accounts for roughly 85 percent of metastatic colorectal cases and has historically been immunotherapy-resistant. Finding ways to sensitize these tumors to immune attack is a top research priority.
This phase I trial, sponsored by City of Hope Medical Center, investigated whether regorafenib could serve as an immunosensitizer when paired with ipilimumab, a CTLA-4 inhibitor, and nivolumab, a PD-1 inhibitor. Regorafenib is an FDA-approved oral multi-kinase inhibitor that targets tumor vasculature and growth signaling pathways. Preclinical evidence suggested it may also modulate the tumor microenvironment to enhance immune infiltration, providing the biological rationale for this combination.
The trial enrolled 39 patients with advanced or metastatic colorectal adenocarcinoma who had progressed on prior chemotherapy. As a phase I study, the primary objective was to determine the optimal dose of regorafenib in combination with fixed doses of the two checkpoint inhibitors, with safety and tolerability as the central focus. Secondary objectives likely included preliminary efficacy signals such as response rate and disease control.
The trial completed in December 2025. While detailed results are not yet available from the abstract alone, the completion of enrollment and follow-up positions this dataset to inform future phase II trial design. If a tolerable and active dose was identified, this triplet could represent a meaningful advance for a patient population with few remaining options after chemotherapy failure.
Caveats include the small phase I sample size, the absence of a control arm, and the focus on dose-finding rather than efficacy. The microsatellite stable population is biologically heterogeneous, and broader applicability will require larger, randomized studies.
Key Findings
- Phase I trial tested regorafenib plus ipilimumab and nivolumab in 39 chemo-resistant MSS metastatic colorectal patients.
- Regorafenib may prime the tumor microenvironment to enhance immune checkpoint inhibitor activity.
- MSS colorectal cancer represents ~85% of metastatic cases and historically does not respond to immunotherapy alone.
- Trial is now completed, with dose-finding and safety as primary endpoints; efficacy data anticipated.
- Combination approach could open a new treatment pathway where no effective immunotherapy currently exists.
Methodology
This is a phase I, dose-escalation trial enrolling 39 patients with microsatellite stable metastatic colorectal adenocarcinoma refractory to chemotherapy. The primary endpoint was determining the safe and recommended dose of regorafenib combined with fixed-dose ipilimumab and nivolumab. Sponsored by City of Hope Medical Center, the trial ran from May 2020 to December 2025.
Study Limitations
This summary is based on the abstract only, as full trial results have not been published or are not publicly available. The phase I design prioritizes safety over efficacy, limiting conclusions about clinical benefit. The small sample size of 39 patients and absence of a randomized control arm restrict generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.